The American Academy of Neurology (AAN) has penned an "evidence-in-focus" report to help neurologists, patients, and their families digest the current evidence on the controversial Alzheimer's drug ...
Time kills deals, as the saying goes. And the biggest deal on the Alzheimer’s front—in terms of improving cognition in the early stages of the disease—is Biogen’s new drug Aducanumab, currently under ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results